Organisation
Department of Pharmaceutics
Department
Projects
221 - 230 of 375
- Cytotoxic cell-mediated delivery of nucleic acid nanoparticles as a
synergistic cancer immunotherapyFrom1 Jan 2017 → 31 Dec 2020Funding: FWO Strategic Basic Research Grant
- Induction of safe but potent anti-tumour responses via lymph node focused nanoparticle-mediated immune activationFrom1 Jan 2017 → 31 Dec 2019Funding: FWO research project (including WEAVE projects)
- Intelligent polymeric nanoparticles for targeted elimination of
tumor-associated macrophages as innovative anti-cancer treatmentFrom1 Jan 2017 → 31 Dec 2020Funding: FWO Strategic Basic Research Grant
- Engineering anti-cancer immunity using polymeric nanoparticles that transform into synthetic cell surface receptors in response to intracellular pHFrom1 Jan 2017 → 31 Dec 2020Funding: FWO research project (including WEAVE projects)
- Unraveling the trichothecene degradation pathway for valorization
in pre- and post-harvest remediationFrom1 Jan 2017 → 31 Dec 2018Funding: FWO Strategic Basic Research Grant
- Identification of individual exosome like vesicles by surface enhanced Raman spectroscopyFrom15 Oct 2016 → 14 Oct 2017Funding: IOF - Industrial Research Fund
- Induction of safe but potent anti-tumour responses via lymph node focused nanoparticle-mediated immune activationFrom1 Oct 2016 → 30 Sep 2019Funding: FWO fellowships
- Exploring UCST behaviour for the design of degradable polymeric drug nanocarriersFrom1 Oct 2016 → 30 Sep 2018Funding: BOF - Other initiatives
- Tenure track appointment in biophysics of the administration of biological drugsFrom1 Oct 2016 → 30 Sep 2021Funding: BOF - ZAP BOF mandates, BOF - tenure track
- Repurposing of cationic amphiphilic drugs as adjuvants to enhance
the cellular delivery of small interfering RNAFrom1 Oct 2016 → 30 Sep 2020Funding: FWO fellowships
Publications
1 - 10 of 1921
- Tailored design of sugar-modified a-GalCer analogues for Th1-polarized immune responses(2018)
Authors: Serge Van Calenbergh
Pages: 42 - 42 - Structural basis for the recognition of C20:2-U+03B1GalCer by the invariant natural killer T-cell receptor-like antibody L363(2012)
Authors: Esther Dawen Yu, Enrico Girardi, Jing Wang, Thien-Thi Mac Mac, Karl OA Yu, Serge Van Calenbergh, Steven A Porcelli, Dirk M Zajonc
Pages: 1269 - 1278 - Common genetic determinants of lung function, subclinical atherosclerosis and risk of coronary artery disease(2014)
Authors: Maria Sabater-Lleal, Aners Mälarstig, Lasse Folkersen, María Soler Artigas, Damiano Baldassarre, Maryam Kavousi, Peter Almgren, Fabrizio Veglia, Guy Brusselle, Albert Hofman, et al.
- Outpatient Pharmacotherapy(2008)
Authors: Guy Brusselle
Pages: 331 - 349 - Properties of the COPD assessment test in a cross-sectional European study(2011)
Authors: PW Jones, Guy Brusselle, RW Dal Negro, M Ferrer, P Kardos, ML Levye, T Perez, JJ Soler Cataluña, T van der Molen, L Adamek, et al.
Pages: 29 - 35 - Mechanistic links between COPD and lung cancer: a role of microRNA let-7?(2014)
Authors: Jae Il Shin, Guy Brusselle
Pages: 70 - 70 - Effect of a 3-month low-dose azithromycin intervention for COPD exacerbations requiring hospitalization on subsequent respiratory events and mortality : the BACE trial(2019)Volume: 199
Authors: W Janssens, K Vermeersch, T Troosters, Guy Brusselle
Number of pages: 1 - Disease-modifying anti-asthmatic drugs(2022)
Authors: Marek Lommatzsch, Guy Brusselle, G. Walter Canonica, David J. Jackson, Parameswaran Nair, Roland Buhl, Johann Christian Virchow
Pages: 1664 - 1668 - I have taken my umbrella, so of course it does not rain(2012)
Authors: DS Postma, Guy Brusselle, A Bush, JW Holloway
Pages: 88 - 89 - Blood eosinophils and smoking history affect outcome with high dose N-acetylcysteine treatment in COPD(2017)Volume: 50
Authors: Alberto Papi, Guy Brusselle, Francesco Sergio, Marco Pannacci, Jinping Zheng, Gerard Criner
Number of pages: 1